Global Monoclonal Antibody for Multiple Myeloma Market 2019 by Company, Regions, Type and Application, Forecast to 2024

Table of Contents

1 Monoclonal Antibody for Multiple Myeloma Market Overview

• 1.1 Product Overview and Scope of Monoclonal Antibody for Multiple Myeloma
• 1.2 Classification of Monoclonal Antibody for Multiple Myeloma by Types
  • 1.2.1 Global Monoclonal Antibody for Multiple Myeloma Revenue Comparison by Types (2019-2024)
  • 1.2.2 Global Monoclonal Antibody for Multiple Myeloma Revenue Market Share by Types in 2018
  • 1.2.3 Elotuzumab
  • 1.2.4 Daratumumab
  • 1.2.5 Siltuximab
  • 1.2.6 Dacetuzumab
  • 1.2.7 Rituximab
  • 1.2.8 Other
• 1.3 Global Monoclonal Antibody for Multiple Myeloma Market by Application
  • 1.3.1 Global Monoclonal Antibody for Multiple Myeloma Market Size and Market Share Comparison by Applications (2014-2024)
  • 1.3.2 Hospital
  • 1.3.3 Drug Center
  • 1.3.4 Clinic
  • 1.3.5 Other
• 1.4 Global Monoclonal Antibody for Multiple Myeloma Market by Regions
  • 1.4.1 Global Monoclonal Antibody for Multiple Myeloma Market Size (Million USD) Comparison by Regions (2014-2024)
  • 1.4.1 North America (USA, Canada and Mexico) Monoclonal Antibody for Multiple Myeloma Status and Prospect (2014-2024)
  • 1.4.2 Europe (Germany, France, UK, Russia and Italy) Monoclonal Antibody for Multiple Myeloma Status and Prospect (2014-2024)
  • 1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Monoclonal Antibody for Multiple Myeloma Status and Prospect (2014-2024)
  • 1.4.4 South America (Brazil, Argentina, Colombia) Monoclonal Antibody for Multiple Myeloma Status and Prospect (2014-2024)
  • 1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Monoclonal Antibody for Multiple Myeloma Status and Prospect (2014-2024)
• 1.5 Global Market Size of Monoclonal Antibody for Multiple Myeloma (2014-2024)

2 Manufacturers Profiles

• 2.1 Bristol Myers Squibb
  • 2.1.1 Business Overview
  • 2.1.2 Monoclonal Antibody for Multiple Myeloma Type and Applications
    • 2.1.2.1 Product A
    • 2.1.2.2 Product B
  • 2.1.3 Bristol Myers Squibb Monoclonal Antibody for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
• 2.2 Abbvie
  • 2.2.1 Business Overview
  • 2.2.2 Monoclonal Antibody for Multiple Myeloma Type and Applications
    • 2.2.2.1 Product A
    • 2.2.2.2 Product B
  • 2.2.3 Abbvie Monoclonal Antibody for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
• 2.3 Janssen Biotech
  • 2.3.1 Business Overview
  • 2.3.2 Monoclonal Antibody for Multiple Myeloma Type and Applications
    • 2.3.2.1 Product A
    • 2.3.2.2 Product B
  • 2.3.3 Janssen Biotech Monoclonal Antibody for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
• 2.4 Karyopharm Therapeutics
  • 2.4.1 Business Overview
  • 2.4.2 Monoclonal Antibody for Multiple Myeloma Type and Applications
    • 2.4.2.1 Product A
    • 2.4.2.2 Product B
  • 2.4.3 Karyopharm Therapeutics Monoclonal Antibody for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
• 2.5 PDL BioPharma
  • 2.5.1 Business Overview
  • 2.5.2 Monoclonal Antibody for Multiple Myeloma Type and Applications
    • 2.5.2.1 Product A
    • 2.5.2.2 Product B
  • 2.5.3 PDL BioPharma Monoclonal Antibody for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
• 2.6 Roche
  • 2.6.1 Business Overview
  • 2.6.2 Monoclonal Antibody for Multiple Myeloma Type and Applications
    • 2.6.2.1 Product A
    • 2.6.2.2 Product B
  • 2.6.3 Roche Monoclonal Antibody for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
• 2.7 Seattle Genetics
  • 2.7.1 Business Overview
  • 2.7.2 Monoclonal Antibody for Multiple Myeloma Type and Applications
    • 2.7.2.1 Product A
    • 2.7.2.2 Product B
  • 2.7.3 Seattle Genetics Monoclonal Antibody for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)

3 Global Monoclonal Antibody for Multiple Myeloma Market Competition, by Players

• 3.1 Global Monoclonal Antibody for Multiple Myeloma Revenue and Share by Players (2014-2019)
• 3.2 Market Concentration Rate
  • 3.2.1 Top 5 Monoclonal Antibody for Multiple Myeloma Players Market Share
  • 3.2.2 Top 10 Monoclonal Antibody for Multiple Myeloma Players Market Share
• 3.3 Market Competition Trend

4 Global Monoclonal Antibody for Multiple Myeloma Market Size by Regions

• 4.1 Global Monoclonal Antibody for Multiple Myeloma Revenue and Market Share by Regions
• 4.2 North America Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2014-2019)
• 4.3 Europe Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2014-2019)
• 4.4 Asia-Pacific Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2014-2019)
• 4.5 South America Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2014-2019)
• 4.6 Middle East and Africa Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2014-2019)

5 North America Monoclonal Antibody for Multiple Myeloma Revenue by Countries

• 5.1 North America Monoclonal Antibody for Multiple Myeloma Revenue by Countries (2014-2019)
• 5.2 USA Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2014-2019)
• 5.3 Canada Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2014-2019)
• 5.4 Mexico Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2014-2019)

6 Europe Monoclonal Antibody for Multiple Myeloma Revenue by Countries

• 6.1 Europe Monoclonal Antibody for Multiple Myeloma Revenue by Countries (2014-2019)
• 6.2 Germany Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2014-2019)
• 6.3 UK Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2014-2019)
• 6.4 France Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2014-2019)
• 6.5 Russia Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2014-2019)
• 6.6 Italy Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2014-2019)

7 Asia-Pacific Monoclonal Antibody for Multiple Myeloma Revenue by Countries

• 7.1 Asia-Pacific Monoclonal Antibody for Multiple Myeloma Revenue by Countries (2014-2019)
• 7.2 China Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2014-2019)
• 7.3 Japan Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2014-2019)
• 7.4 Korea Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2014-2019)
• 7.5 India Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2014-2019)
• 7.6 Southeast Asia Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2014-2019)

8 South America Monoclonal Antibody for Multiple Myeloma Revenue by Countries

• 8.1 South America Monoclonal Antibody for Multiple Myeloma Revenue by Countries (2014-2019)
• 8.2 Brazil Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2014-2019)
• 8.3 Argentina Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2014-2019)
• 8.4 Colombia Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2014-2019)

9 Middle East and Africa Revenue Monoclonal Antibody for Multiple Myeloma by Countries

• 9.1 Middle East and Africa Monoclonal Antibody for Multiple Myeloma Revenue by Countries (2014-2019)
• 9.2 Saudi Arabia Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2014-2019)
• 9.3 UAE Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2014-2019)
• 9.4 Egypt Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2014-2019)
• 9.5 Nigeria Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2014-2019)
• 9.6 South Africa Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2014-2019)

10 Global Monoclonal Antibody for Multiple Myeloma Market Segment by Type

• 10.1 Global Monoclonal Antibody for Multiple Myeloma Revenue and Market Share by Type (2014-2019)
• 10.2 Global Monoclonal Antibody for Multiple Myeloma Market Forecast by Type (2019-2024)
• 10.3 Elotuzumab Revenue Growth Rate (2014-2024)
• 10.4 Daratumumab Revenue Growth Rate (2014-2024)
• 10.5 Siltuximab Revenue Growth Rate (2014-2024)
• 10.6 Dacetuzumab Revenue Growth Rate (2014-2024)
• 10.7 Rituximab Revenue Growth Rate (2014-2024)
• 10.8 Other Revenue Growth Rate (2014-2024)

11 Global Monoclonal Antibody for Multiple Myeloma Market Segment by Application

• 11.1 Global Monoclonal Antibody for Multiple Myeloma Revenue Market Share by Application (2014-2019)
• 11.2 Monoclonal Antibody for Multiple Myeloma Market Forecast by Application (2019-2024)
• 11.3 Hospital Revenue Growth (2014-2019)
• 11.4 Drug Center Revenue Growth (2014-2019)
• 11.5 Clinic Revenue Growth (2014-2019)
• 11.6 Other Revenue Growth (2014-2019)

12 Global Monoclonal Antibody for Multiple Myeloma Market Size Forecast (2019-2024)

• 12.1 Global Monoclonal Antibody for Multiple Myeloma Market Size Forecast (2019-2024)
• 12.2 Global Monoclonal Antibody for Multiple Myeloma Market Forecast by Regions (2019-2024)
• 12.3 North America Monoclonal Antibody for Multiple Myeloma Revenue Market Forecast (2019-2024)
• 12.4 Europe Monoclonal Antibody for Multiple Myeloma Revenue Market Forecast (2019-2024)
• 12.5 Asia-Pacific Monoclonal Antibody for Multiple Myeloma Revenue Market Forecast (2019-2024)
• 12.6 South America Monoclonal Antibody for Multiple Myeloma Revenue Market Forecast (2019-2024)
• 12.7 Middle East and Africa Monoclonal Antibody for Multiple Myeloma Revenue Market Forecast (2019-2024)

13 Research Findings and Conclusion

14 Appendix

• 14.1 Methodology